ProCap Insights · July 1, 2026
Eli Lilly grows faster than Big Tech stocks but has a fraction of the risk
The market files Eli Lilly under defensive pharma, an outsider in the trillion-dollar AI club.
Subscribe to read the full report
Unlimited access to every research report we publish.
Already a member?